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Objective. In a sibpair study of osteoarthritis
(OA) patients, we investigated whether, upon stimula-
tion with lipopolysaccharide (LPS), variations in the
innate ex vivo production of interleukin-1 (IL-1),
IL-1 receptor antagonist (IL-1Ra), IL-10, and tumor
necrosis factor  (TNF) in whole-blood assays contrib-
ute to the risk of OA.
Methods. Data from 305 patients with OA at
multiple sites (hand, knee, hip, and spine), whose
median age was 60 years (range 43–79 years), were
compared with those from 137 controls. OA was defined
in accordance with the American College of Rheumatol-
ogy criteria. Whole-blood samples were stimulated with
LPS (10 ng/ml). In the supernatants, cytokines were
measured by enzyme-linked immunosorbent assay.
Odds ratios (ORs) were used as measures of the relative
risk of OA in relation to quartiles of IL-1, IL-1Ra,
TNF, and IL-10 production. The ORs were adjusted
for sex and age, and 95% confidence intervals (95% CIs)
were computed using robust standard errors to take into
account the intrafamily effect.
Results. Subjects in the highest quartile of IL-1
and IL-1Ra had an increased risk of OA (OR 3.3, 95%
CI 1.4–7.9 and OR 8.0, 95% CI 3.7–17.4, respectively),
while subjects in the lowest quartile of IL-10 had a
3-fold increased risk of OA (OR 3.1, 95% CI 1.5–6.5).
High innate ex vivo production of TNF was not asso-
ciated with an increased risk of OA.
Conclusion. Subjects with a high innate ex vivo
production of IL-1 and IL-1Ra and low innate ex vivo
production of IL-10 have an increased risk of OA. These
results suggest that a proportion of the genetic suscep-
tibility to OA may be encoded for by variations in innate
cytokine activity.
Osteoarthritis (OA) is the most frequently occur-
ring joint disease and is an important cause of pain and
disability in the general population. The hereditary basis
of this disease has become apparent from studies of
familial aggregation as well as studies of twins. These
studies have shown that a considerable fraction of
variation in disease susceptibility can be explained by
genetic factors (1). Nonetheless, despite numerous
genome-wide scans and association studies that have
identified many of the linkage regions, it remains un-
clear which genes are involved (2).
In recent years, there has been increasing interest
in the role of cytokines as mediators of joint damage and
inflammation in the pathogenesis of OA. The most
direct observation linking OA and inflammation comes
from studies in which an association was found between
progression of structural joint changes and the presence
of synovitis and inflammation in patients with OA (3).
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In OA, synovitis is believed to be a reactive process as a
result of cartilage destruction and the release of
cartilage-degradation products in the synovial fluid (4).
Loss of cartilage matrix results from the secretion of
enzymes by chondrocytes in response to catabolic cyto-
kines produced within the joint (5). These cytokines are
most likely released by cells in the synovial fluid and
synovial tissue, as well as by chondrocytes. In addition to
proinflammatory cytokines, antiinflammatory cytokines
are also present in OA joint tissues. The balance among
these cytokines may determine the severity of cartilage
damage in OA (6).
Of the proinflammatory cytokines, interleukin-1
(IL-1) and tumor necrosis factor  (TNF) are the
most prominent in OA. These cytokines have been
shown in vitro to be expressed and to stimulate the
production of other cytokines, such as IL-8, IL-6, and
leukemia inhibitory factor, as well as their own produc-
tion, leading to accelerated damage of articular tissue
(5). Studies in animal models suggest that cartilage-
destructive processes are mainly driven by IL-1,
whereas TNF is involved in the early stages of inflam-
mation (7).
IL-1 receptor antagonist (IL-1Ra) is a competi-
tive inhibitor of the IL-1 receptor, and its production
rises in response to IL-1 production. Although an
excess level of IL-1Ra is found in OA articular tissue, it
has been shown, in in vitro experiments, that a large
amount of IL-1Ra is necessary to inhibit IL-1 activity
(5). Additional data supporting the role of IL-1 in OA
susceptibility is provided by genetic studies in OA that
have demonstrated linkage on the 2q chromosome,
which encompasses the ligand gene cluster at 2q12–q13,
composed of IL1B, IL1A, and IL1RN (8–10).
A number of cytokines, such as IL-4, IL-10, and
IL-13, have been shown in vitro to inhibit the activity of
proinflammatory cytokines (11). Furthermore, these an-
tiinflammatory cytokines have been found in increased
levels in the synovial fluid of OA patients (5). Thus, the
metabolic state of chondrocytes is under the influence of
a complex network of cytokines. However, in OA, the
exact roles of cytokines other than IL-1 and TNF in
the activation and modulation of possible cascade reac-
tions have not yet been clearly established (11).
Studies of twins have shown that the ex vivo
production of cytokines induced by lipopolysaccharide
(LPS) in whole-blood samples varies by 60–75% on the
basis of heritability alone (12), and that subjects may be
characterized as high or low producers of these cyto-
kines (13). Polymorphisms in the promoter region of
IL-1 and IL-10 have been associated with variation in
the production of cytokines (14,15). Furthermore, vari-
ation in innate ex vivo cytokine production upon LPS
stimulation has been associated with the susceptibility to
and severity of diseases such as systemic lupus erythem-
atosus (SLE) (16).
Given the role of cytokines in OA pathophysiol-
ogy and the genetic variation of ex vivo cytokine produc-
tion upon LPS stimulation in humans, the question
arises whether genetic variation in cytokine production
contributes to OA susceptibility. Therefore, in a cohort
of patients with familial symptomatic OA at multiple
sites, we investigated whether variations in the ex vivo
production of IL-1, IL-1Ra, IL-10, and TNF upon
LPS stimulation, measured in whole-blood assays, con-
tribute to the risk of OA.
PATIENTS AND METHODS
Patient population. The present study is part of the
ongoing Genetics, Arthrosis and Progression (GARP) study.
The GARP study is aimed at the identification of determinants
of OA susceptibility and progression, and involves Caucasian
sibpairs of Dutch ancestry. The population predominantly
comprises individuals with symptomatic OA at multiple sites.
Recruitment and clinical evaluation. The index pa-
tients (probands; n  1,874), ages between 40 and 70 years,
had symptomatic OA in the hands, knees, or hips, which was
diagnosed by rheumatologists, orthopedic surgeons, and gen-
eral practitioners in Leiden, The Hague, Delft, Haarlem, and
Amsterdam, The Netherlands. Patients were informed of the
study by mail. Of the 1,874 patients, 833 interested probands
were sent a questionnaire to obtain demographic data, medical
history, symptoms and signs of OA, and family history of OA.
Subsequently, eligible probands with a positive family history
of OA in first-degree relatives (n  521) were requested to
introduce a sibling who had “joint complaints,” and this sibling
was also asked to complete a mailed questionnaire. Of these
probands, 353 had at least 1 sibling with “joint complaints.”
One hundred thirty-nine of these siblings either did not meet
the GARP criteria (n  47) or were unwilling to participate
(n  92), resulting in 214 eligible sibpairs.
After we obtained their informed consent, eligible
sibpairs were invited to the outpatient clinic to undergo
physical and radiographic examinations, provide blood and
urine samples for assessment of biomarkers and DNA, and
complete standardized questionnaires. All sibpairs were exam-
ined by one medical doctor (NR). Questionnaires were verified
and data were collected on physical functioning and quality of
life. Of the 214 sibpairs, 191 were included in the GARP study
from August 2000 to March 2003.
Exclusion criteria. Patients with secondary OA and
familial syndromes with a Mendelian inheritance pattern were
excluded. Conditions that were considered to be secondary OA
were 1) major congenital or developmental diseases and bone
dysplasias, 2) major local factors such as severe scoliosis and
hypermobility, 3) certain metabolic diseases associated with
joint disease such as hemochromatosis and Wilson’s disease, 4)
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inflammatory joint diseases such as rheumatoid arthritis (RA),
5) other bone diseases such as osteitis deformans and osteo-
chondritis, and 6) intraarticular fractures. Patients with a
shortened life expectancy were also excluded. Crystal deposi-
tion arthropathies (except in the case of severe polyarticular
gout), diabetes mellitus, or thyroid conditions were not con-
sidered as exclusion criteria.
OA diagnosis. For the present study, all patients with
symptomatic OA at multiple sites were included. Symptomatic
OA at multiple sites was defined as the presence of OA
symptoms in the hand joints or 2 or more of the following sites:
hands, spine (cervical or lumbar), knee, or hip.
Symptomatic OA in the hand joints was defined ac-
cording to the American College of Rheumatology (ACR)
criteria (17), which requires the presence of pain or stiffness in
the hand joints on most days of the prior month, in addition to
3 of the following 4 criteria: bony swelling of 2 of the 10
selected joints (second and third distal interphalangeal [DIP]
joints bilaterally, second and third proximal interphalangeal
[PIP] joints bilaterally, and first carpometacarpal [CMC1]
joint), bony swelling of 2 DIP joints, 3 swollen meta-
carpophalangeal (MCP) joints, and deformity of at least 1 of
the 10 selected joints. Symptomatic OA in the knee and hip
was defined in accordance with the ACR recommendations for
knee and hip OA (18,19). Knee OA was defined as pain or
stiffness in the knee joints for most days of the prior month,
and osteophytes at joint margins of the tibiofemoral joint
(radiographic spurs). Hip OA was defined as pain or stiffness
in the groin and hip region on most days of the prior month, in
addition to femoral or acetabular osteophytes or joint space
narrowing on radiographic examination. The presence of joint
prostheses in the hips or the knees as a result of end-stage OA
was included as OA in that particular joint. Spine OA (cervical
and lumbar) was defined as pain or stiffness in the spine on
most days of the prior month, in addition to a Kellgren/
Lawrence (K/L) score of 2 in at least 1 disc or 1 apophyseal
joint.
Radiographs. Conventional radiographs of the hands
(dorsovolar view), knees (posteroanterior [PA] and lateral
views of weight-bearing/semiflexed knees), hips (PA view),
Figure 1. Ex vivo production of interleukin-1 (IL-1), IL-1 receptor antagonist (IL-1Ra), IL-10,
and tumor necrosis factor  (TNF-a) upon lipopolysaccharide stimulation in patients with
osteoarthritis (OA) and in healthy controls. Data are presented as box plots, where the boxes
represent the 25th to 75th percentiles, the lines within the boxes represent the means, and the lines
outside the boxes represent the 5th and 95th percentiles. Asterisks indicate outliers.
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lumbar (PA and lateral views), and cervical spine (antero-
posterior, lateral, and transbuccal views) were obtained for all
participants. This was performed in a standard manner with a
fixed film-focus distance and a fixed joint position. All radio-
graphs were obtained by a single experienced radiology tech-
nician. Conventional radiographs were scored by a single
experienced musculoskeletal radiologist (HK) for osteophytes
in the knees and hips and joint space narrowing in the hips.
In addition to the hands (DIPs, PIPs, and CMC1) and
the discs and apophyseal joints of the cervical and lumbar
spine, the hips and tibiofemoral joints of the knees were also
scored according to the K/L scale, utilizing the original atlas
(20). The K/L scale is a 5-point scoring system that rates the
severity of OA in an ascending manner, based on the presence
of osteophytes, joint space narrowing, sclerosis, and degener-
ative cysts. A K/L score of 2 defines disease severity in a
particular joint.
Controls. For comparison, blood samples from 137
healthy control individuals were used. The control subjects
belonged to 54 families who had participated as controls in a
previous study on multiple sclerosis and SLE, and were
spouses and first-degree relatives of the patients with SLE or
multiple sclerosis (16).
Whole-blood stimulation system. Whole-blood sample
stimulation was performed as previously described (21).
Briefly, blood samples were collected in pyrogen-free heparin-
ized tubes (Endotube; Chromogenix, Mo¨lndal, Sweden).
Eight-milliliter whole-blood samples were diluted 1:1 with
RPMI 1640 (Gibco Life Technologies, Paisley, UK) and
stimulated with 10 ng/ml Escherichia coli LPS (Difco, Detroit,
MI). To minimize the influence of circadian rhythms and
measurement errors, blood samples were obtained between
8:00 AM and 11:00 AM, the time frame between blood collection
and stimulation was 1.5 hours, and all stimuli were per-
formed in the same endotoxin batch. The simultaneous mea-
surement of all samples was possible, since spare samples from
controls had been stored. One medium-diluted blood sample
without LPS was used as a negative control. After 4-hour and
24-hour incubations, samples were centrifuged twice (at 600g)
and the supernatants were stored at 70°C. TNF was mea-
sured in 4-hour samples and IL-1, IL-1Ra, and IL-10 produc-
tion was measured in 24-hour samples in one batch, by
enzyme-linked immunosorbent assay according to the manu-
facturer’s guidelines (Central Laboratory of the Blood Trans-
fusion Service, Amsterdam, The Netherlands).
Statistical analysis. The difference in the innate ex
vivo production (mean levels) of IL-1, IL-1Ra, TNF, and
IL-10 between the patients and the controls was calculated by
linear mixed models with a random intercept to adjust for the
familial effect within the sibpairs. Since the ex vivo production
of cytokines was not normally distributed, a log transformation
was performed. Estimates of fixed effects were reported with
95% confidence intervals (95% CIs), which excluded the value
of 1 in case of statistical significance. The estimates represent
the magnitude of the difference in the mean innate ex vivo
production of IL-1, IL-1Ra, TNF, and IL-10 between the
patients and the controls.
Odds ratios (ORs), as measures of relative risk, were
calculated using logistic regression to adjust for age and sex. To
take into account the intrafamily effect, robust standard errors
were computed using the statistical program Stata, version 7.0
(Stata, College Station, TX). The ORs are presented with 95%
CIs. Cytokines were divided into quartiles of production levels,
based on the distribution in controls. Since pro- and antiin-
flammatory cytokines act antagonistically, the modifying effect
of one cytokine on the other was estimated by analyzing the
effect of IL-1 and IL-1Ra simultaneously and of TNF and
IL-10 simultaneously, using multivariate logistic regression
models.
RESULTS
Of the 191 sibpairs included in the GARP study,
156 had symptomatic OA at multiple sites and were
included in the present study. Seven patients were
excluded from the analyses because no whole-blood
samples had been obtained from these patients. Of the
remaining 305 patients, levels of IL-1Ra and IL-10 were
missing for 1 patient each and levels of TNF were
missing for 2 patients due to technical difficulties.
The characteristics of the 305 patients in the
present study are shown in Table 1. The median age of
the patients was 60 years (range 43–79 years) and the
majority of the patients (82%) were women. Hand OA
and spine OA were the most common types of OA in
this patient population. Of the 248 patients with OA
affecting multiple sites in the hands, 37 did not have
symptomatic OA at other sites, although 35 of the 37
also had radiographic OA at other sites. Of the 246
patients with the diagnosis of spine OA, the apophyseal
joints of 240 patients were affected by OA, irrespective
of disc degeneration. The median age of the controls was
50 years (range 12–83 years) and 55% of the controls
were women.
The mean innate ex vivo production of IL-1 was
1.15 pg/ml higher in patients than in controls (95% CI
1.06–1.25). For IL-1Ra, the mean ex vivo production was
1.12 pg/ml higher in patients than in controls (95% CI
1.07–1.17). The mean ex vivo production of IL-10 was
1.04 pg/ml lower in patients (95% CI 0.90–14.9) and the
mean ex vivo production of TNF was 0.98 pg/ml lower
in patients (95% CI 0.93–1.04) than in controls.
Table 1. Characteristics of the 305 patients with familial symptom-
atic osteoarthritis (OA) at multiple sites
Women, no. (%) 251 (82)
Age, median (range) years 60 (43–79)
Body mass index, median (range) kg/m2 26 (19–46)
Subtypes of symptomatic OA, no. (%)
Hand 248 (81)
Spine 246 (81)
Hip 76 (25)
Knee 107 (35)
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Table 2 shows the risk of having OA according to
quartiles of IL-1, IL-1Ra, TNF, and IL-10 produc-
tion. Subjects in the highest quartile of IL-1 production
had a 3-fold increased risk of having OA (OR 3.3, 95%
CI 1.4–7.9), and subjects in the highest quartile of
IL-1Ra production had an 8-fold increased risk of OA
(OR 8.0, 95% CI 3.7–17.4), both in comparison with
those in the lowest quartile. Furthermore, a trend to-
ward an increased risk of OA was seen with increasing ex
vivo production of IL-1 and IL-1Ra.
Subjects in the highest quartile of IL-10 produc-
tion had a decreased risk of OA (OR 0.32, 95% CI
0.2–0.7). When high IL-10 production served as the
reference, based on data showing that a low innate
production of IL-10 predisposes individuals to an in-
flammatory state, a trend toward an increased risk of
OA was observed with decreasing ex vivo IL-10 produc-
tion, in comparison with individuals in the highest
quartile (second quartile OR 2.1, 95% CI 1.0–4.6, third
quartile OR 2.4, 95% CI 1.1–5.4, fourth [lowest] quartile
OR 3.1, 95% CI 1.5–6.5). High innate ex vivo production
of TNF was not associated with an increased risk of
OA.
In order to assess the independent effect of each
cytokine, IL-1 and IL-1Ra together and TNF and
IL-10 together were analyzed using multivariate models.
These analyses did not materially affect the estimates
found in the univariate model (data not shown).
DISCUSSION
Subjects with high innate ex vivo production of
IL-1 and IL-1Ra and low IL-10 production upon LPS
stimulation had an increased risk of familial OA at
multiple sites. High innate ex vivo production of TNF
did not increase the risk of OA.
IL-1 contributes to the pathogenesis of OA by
several pathways. In vitro, human articular chondro-
cytes, when stimulated by IL-1, dramatically increase
the expression of matrix-degrading proteinases, such as
matrix metalloproteinases (MMPs), and induce the pro-
duction of nitric oxide, a catabolic mediator in cartilage
(22). In addition, IL-1 inhibits the biosynthesis of
cartilage proteoglycans and collagens and leads to the
synthesis of other inflammatory cytokines (11). The
biologic activity of IL-1 in OA tissue is further en-
hanced by the increased number of type I IL-1 receptors
on OA chondrocytes and synovial fibroblasts, which may
account for the increased susceptibility of OA cartilage
to degradation by IL-1 when compared with similar
cartilage from subjects without arthritis (23). OA animal
models provide further support for the role of IL-1 in
OA. In experimental models, intraarticular injections of
IL-1Ra have been shown to block IL-1 action and
reduce OA progression (24). Furthermore, the in vivo
transfection of the IL-1Ra gene into the OA knee joints
of dogs or rabbits was shown to be successful in reducing
the progression of OA lesions (25).
It has been suggested that IL-1Ra is released
from cells along with IL-1 in response to the same
stimulus and is thus present at high levels in OA patients
(4,26). In the present study, we found that patients with
a high innate ex vivo production of IL-1 as well as
IL-1Ra had an increased risk of OA. The simultaneous
presence of an increased ability to produce IL-1Ra and
IL-1 indicates an increased responsiveness, possibly
through a more sensitive IL-1 and IL-1Ra gene activa-
tion route in this disease. Since the risk of OA in our
study was associated with an independent innate produc-
tion of both cytokines, genetic variants in both loci may
contribute to this effect. A direct effect of the IL-1 gene
cluster has been suggested by various studies reporting a
Table 2. Risk of having OA in relation to quartiles of innate ex vivo
production of IL-1, IL-1Ra, IL-10, and TNF upon lipopolysaccha-
ride stimulation in whole-blood assays*
Cytokine, quartiles
(pg/ml)
No. in quartile
Adjusted OR
(95% CI)†
OA patients
(n  305)
Controls
(n  137)
IL-1
397–1,589 45 34 1.0
1,590–2,724 80 35 1.7 (0.9–3.4)
2,725–4,392 92 34 3.2 (1.5–6.6)
4,393–21,019 88 34 3.3 (1.4–7.9)
IL-1Ra
7,908–15,002 25 34 1.0
15,003–18,942 53 35 2.3 (1.0–5.4)
18,943–24,445 98 34 5.4 (2.1–14.2)
24,446–73,932 128 34 8.0 (3.7–17.4)
IL-10
4–689 130 34 1.0
690–967 81 34 0.74 (0.4–1.5)
968–1,331 65 35 0.73 (0.3–1.5)
1,332–3,088 28 34 0.32 (0.2–0.7)
TNF
1,534–6,462 107 34 1.0
6,463–8,309 74 34 0.62 (0.3–1.2)
8,310–10,722 62 35 0.93 (0.4–2.0)
10,723–21,405 60 34 0.58 (0.3–1.2)
* Levels of interleukin-1 receptor antagonist (IL-1Ra), IL-10, and
tumor necrosis factor  (TNF) were missing for 1 patient, 1 patient,
and 2 patients, respectively, due to technical difficulties. OA 
osteoarthritis.
† Odds ratios (ORs) are adjusted for age and sex. The 95% confidence
intervals (95% CIs) are based on robust standard errors to take into
account the intrafamily effect.
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positive linkage to chromosome 2q12–q14, containing
the IL-1 cluster, and OA (8–10). Leppa¨vuori et al, for
example, found linkage in this region with OA in the
DIP joints (8). Two other groups of investigators found
an association between the IL-1 gene cluster and the
occurrence of end-stage symptomatic OA among pa-
tients who underwent joint replacement of the knee or
hip (9,27), and most recently, Meulenbelt and associates
found a predisposition for radiographic hip OA in
carriers of the IL1B 211T allele and the IL1RN
variable-number tandom repeat allele 2 (10).
In the present study, a high innate production of
TNF did not increase the risk of OA. Experiments in
animal models of arthritis have shown that TNF and
IL-1 have separate activities. These studies have shown
that TNF injections in rodents significantly reduce
mononuclear cell infiltration in the joint, and that TNF
is substantially less important than IL-1 in cartilage
destruction (7). The distinct effects of TNF and IL-1
have been shown in the streptococcal cell wall arthritis
model. In this model it was shown that blocking IL-1
with antibodies produced little or no suppression of
inflammation, but led to the normalization of the chon-
drocyte synthetic function. This was in contrast to TNF
blockade, which led to an efficient reduction in swelling
but did not have an effect on chondrocyte synthetic
function (28).
In our study, we also found a higher risk of OA in
subjects with a low ex vivo production of IL-10. Antiin-
flammatory cytokines such as IL-10 have been reported
to be synthesized in increased amounts either spontane-
ously by synovial membrane and cartilage (4) or after
stimulation of chondrocytes with IL-1 or TNF (11).
Experiments in synovial tissue cultures have shown that
IL-10 inhibits the production of TNF and IL-1 and
decreases the levels of MMPs produced by macrophages
and fibroblast-like synoviocytes (29). Although the anti-
inflammatory effects of IL-10 have been demonstrated
in RA, its role in OA is still unclear. Based on experi-
mental data in arthritis models, it is, however, conceiv-
able that a low innate production of IL-10 can contribute
to the catabolic state found in OA. Furthermore, the low
innate IL-10 production can be a direct effect of genetic
variation at the IL-10 locus (12).
In OA, inflammation is believed to be important
in the development and progression of disease (3,4).
Although synovial inflammation in OA is often believed
to be reactive to cartilage breakdown products in syno-
vium (4,11), a recent study investigating synovial tissue
samples from patients with early knee OA has shown a
greater mononuclear cell infiltration and hyperplasia of
the synovial lining than in late OA, suggestive of dereg-
ulation of inflammatory pathways in early stages of this
disease (30). This finding implicates the role of cytokines
in early stages of disease development, even before
extensive damage to the cartilage has taken place.
In the present study, ex vivo production of cyto-
kines in whole-blood assays was used to classify subjects
as high or low producers. In whole blood, higher values
of cytokine production and smaller individual variation
were found in comparison with production by peripheral
blood mononuclear cells (PBMCs) (31). The difference
in the level of ex vivo cytokine production in whole-
blood assays as compared with PBMC assays is sug-
gested to be related to the isolation processes. The
methods used to separate PBMCs modify lymphocyte:
monocyte ratios, resulting in a substantial reduction in
monocyte concentrations. The modified lymphocyte:
monocyte ratios in isolated PBMCs may thus affect
qualitative and quantative production of cytokines. In
whole-blood stimulation, not only are natural cell-to-cell
interactions preserved, but also circulating stimulatory
and inhibitory mediators are present at their normal
concentration (32). A previous study by Fraenkel and
associates (33) investigated the association of OA with
PBMC production of IL-1, IL-1Ra, and TNF upon
LPS stimulation. The investigators failed to detect an
increased production of these cytokines in 703 subjects
with radiographic OA in the knees or the hands. The
discrepancy between these findings and the results in the
present study may thus be a reflection of the difference
in the assays that were used and the different phenotype
definitions that would possibly lead to selection of
patient groups enriched for different genetic effects.
In order to minimize measurement errors, sam-
ples from patients and controls in this analysis were
measured on the same day and with the same batch of
reagents, although it has been shown that the misclassi-
fication of subjects as high or low cytokine producers
merely on the basis of laboratory error is unlikely (21).
All analyses in the present study were performed with
correction for age and sex, since the patients in the
present study were considerably older than the controls
and consisted of more women. The LPS-induced pro-
duction of cytokines has been shown to be sex- and
age-specific (34).
The response rate in the GARP study was low, at
44%. This may be attributed partly to the recruitment
procedure. In order to recruit probands who met both
the criterion of multiple sites affected and the criterion
of having a family history of OA, a very broad approach
to patient recruitment was undertaken. OA patients
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from participating centers who had knee, hip, or hand
involvement were approached by mail to inform them of
the study, including its familial aspect. It is conceivable
that probands without a familial history of OA did not
respond. This hypothesis is further supported by a higher
response rate of 70% of the siblings.
It is unlikely that the selection procedure biased
our results. In the present study, the innate ex vivo
production of cytokines was investigated in patients with
an endogenous susceptibility to OA, marked by a clear
family history of this disease and involvement of multi-
ple anatomic sites. Although patients were recruited
from different clinical settings and the multiple-site
involvement included the combination of different joint
sites with OA, we believe that this phenotype is a
homogeneous one. A separate analysis of the patient
population (results not shown) showed that the ex vivo
production of the cytokines under study in patients with
hand involvement was not materially different from that
among patients with knee or hip involvement. Further-
more, we did not observe an association between OA
severity, as defined by the total K/L score and the
number of joint sites affected, and the ex vivo cytokine
production (results not shown).
The prevalence of OA among the controls in the
present study was unknown. However, one can speculate
what proportion might have had OA based on the
prevalence of familial symptomatic OA at multiple sites.
Although the exact prevalence of this phenotype has not
been established in the population, a prevalence of
14% seems realistic. This estimation is based on data
from the Rotterdam population-based study (1), in
which generalized radiographic OA has been reported
to occur in 14% of the population ages 55–65 years
(Slagboon E: personal communication). We expect that
the proportion of persons with OA included in the
GARP study is lower due to the extra requirements for
inclusion in the GARP study, which were the presence of
symptoms and the familial nature of OA.
The present study results suggest that an innate
variation in the production of IL-1, IL-1Ra, and IL-10
independently contributes to OA susceptibility in famil-
ial cases. Furthermore, these results complement data
from in vitro studies and animal models that implicate
IL-1 as the prominent cytokine involved in the
cartilage-destructive process, and stimulate research
into treatment possibilities with structure modifiers such
as IL-1 inhibitors (e.g., diacerein) (35).
Based on the results of the present study, further
investigation of the role of IL-10, functional IL-10
polymorphisms, as well as IL-1 and IL-1Ra in OA is
warranted. Whether these results can be generalized to
other OA populations needs to be assessed in future
studies, since the results in the present study are based
on a patient population with a specific phenotype,
comprising symptomatic OA, radiographically con-
firmed OA at multiple sites, and a clear familial predis-
position for this disease.
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